Generic Name and Formulations:
Timolol (as hemihydrate) 0.25%, 0.5%; oph. soln; contains benzalkonium chloride.
Indications for BETIMOL:
1 drop twice daily.
Overt heart failure. Cardiogenic shock. Sinus bradycardia. 2nd- or 3rd-degree AV block. Asthma. Severe COPD.
Discontinue if heart failure develops and prior to surgery. Not for use as sole agent in narrow-angle glaucoma. Avoid abrupt cessation. Cerebrovascular insufficiency. Diabetes. COPD. Bronchospastic disease. May mask signs of hypoglycemia, thyrotoxicosis. Myasthenia gravis. Bacterial keratitis. Measure IOP after 4 wks of treatment. Pregnancy (Cat.C). Nursing mothers: not recommended.
May potentiate systemic β-blockers, reserpine. May cause conduction defects with calcium channel blockers, digitalis. May antagonize β-agonists. May block epinephrine.
Ocular irritation, eyelid erythema, conjunctival injection, headache, epiphora, photophobia. Systemic β-blocking effects (bradycardia, arrhythmias, hypotension, bronchospasm, heart failure).
Soln—5mL, 10mL, 15mL
- 5ml of 0.5% eye droppers (Qty:1)
- appx. price $79.00
- McDonald's and the Microbiome: What Effect Does Junk Food Have on Gut Bacteria?
- When the Doctor is Depressed: One Clinician Tells His Story
- Spice + Statin Likely Culprit in Patient with Acute Hepatitis
- Most Distinctive Causes of Death Mapped by U.S. State
- First Non-Surgical Tx for "Double Chin" Gains FDA Approval
- Heart Rate May Be an Indicator of Future Diabetes Risk
- Probiotic Mixture VSL#3 Shows Promise for Crohn's Recurrence
- Study: Beloranib Appears Safe, Efficacious for Weight Loss in Obesity
- Progress Toward Mind-Controlled Robotic Limbs
- Response to Resistance Exercise Depends on a Person's Genetic Risk for Obesity